Abstract
lesions absorption rate (12th mos: RR 1.26, 95% CI 1.09 to 1.46, n=3; 18thmos: RR 1.18, 95%CI 1.07 to 1.30, n=6) and pulmonary cavity closure rate by radiological examination (18th mos: RR 1.24, 95%CI 1.01 to 1.51; n=4), relapse rate (RR 0.28, 95%CI 0.16 to 0.50, n=4), and abnormal liver function (RR 0.56, 95% CI 0.46 to 0.69, n=14). Conclusion: CHM as an adjuvant to anti-TB chemotherapy may have beneficial effect for MDR-TB in terms of bacteriological and radiological outcomes, and is safe. However, due to poor methodology of the included trials, a confirmative conclusion needs to be supported through further robust clinical trial. Contact: Mei Wang, linhan616@126.com
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
